Skip to main content

Lymphatic Filariasis

3
Pipeline Programs
1
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
3100%
+ 1 programs with unclassified modality

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
4 programs
3
AlbendazolePhase 2Small Molecule1 trial
AlbendazolePhase 2Small Molecule1 trial
DEC/AlbendazolePhase 2Small Molecule1 trial
Research for Elimination of Lymphatic Filariasis (ICIDR)N/A1 trial
Active Trials
NCT00406627Completed117,500Est. Dec 2011
NCT00511004Completed40Est. Feb 2014
NCT00339417Completed1,000Est. Aug 2011
+1 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Allergy TherapeuticsAlbendazole
Allergy TherapeuticsDEC/Albendazole
Allergy TherapeuticsAlbendazole
Allergy TherapeuticsResearch for Elimination of Lymphatic Filariasis (ICIDR)

Clinical Trials (4)

Total enrollment: 119,540 patients across 4 trials

Effect of Albendazole Dose on Treatment of Lymphatic Filariasis

Start: Jul 2007Est. completion: Feb 201440 patients
Phase 2Completed

Effect of Albendazole Dose on Clearance of Filarial Worms

Start: Sep 2006Est. completion: Apr 20111,000 patients
Phase 2Completed

Effect of Albendazole Dose on Clearance of Filarial Worms

Start: Feb 2006Est. completion: Aug 20111,000 patients
Phase 2Completed
NCT00406627Allergy TherapeuticsResearch for Elimination of Lymphatic Filariasis (ICIDR)

Research for Elimination of Lymphatic Filariasis (ICIDR)

Start: Dec 2006Est. completion: Dec 2011117,500 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

Small Molecule is the dominant modality (100% of programs)
1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.